FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.
What happened
FDA reviewed Tides Medical's website for APLICOR 3D, last visited in October 2026, and records; it says the firm distributes the device in the U.S. without marketing clearance or approval. FDA says APLICOR 3D is adulterated because no approved premarket approval (PMA) or investigational device exemption (IDE) is in effect, and misbranded because the firm did not submit the required 510(k) premarket notification. The letter also says the firm claimed a Class I liquid medication dispenser exemption, but the product's stated wound-care uses exceed that exemption.
What FDA found
FDA says APLICOR 3D is adulterated because there is no approved PMA or IDE for the device.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)FDA says APLICOR 3D is misbranded because the firm did not timely notify FDA before commercial distribution.
section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)FDA says the firm's Class I liquid medication dispenser exemption does not apply because APLICOR 3D is intended for wound-care uses different from that classification.
21 CFR 880.6430; 21 CFR 880.9
What FDA wants
FDA requests that Tides Medical stop activities that make APLICOR 3D illegally marketed, including commercial distribution for the stated uses. The firm must respond in writing within 15 business days with corrective actions or its reasoning and supporting information.
Who should pay attention
- wound care clinics and providers offered APLICOR 3D
- distributors of unapproved wound-care devices
- companies relying on Class I exemptions for devices with expanded uses
This is a summary. Read the original letter on fda.gov.